Analysis of Meloxicam in accordance with the United States Pharmacopoeia

Significance of the Topic

Meloxicam, a widely prescribed non‐steroidal anti‐inflammatory drug (NSAID), requires accurate quantification and impurity profiling to ensure safety and efficacy in pharmaceutical products.
The United States Pharmacopoeia (USP) sets stringent analytical standards for meloxicam quality control, making robust chromatographic methods essential for compliance and patient safety.

Study Objectives and Overview

This application note demonstrates a reversed‐phase high‐performance liquid chromatography (RP‐HPLC) method following the USP monograph for meloxicam analysis.
The primary aims are to achieve clear separation of meloxicam and its related compounds A and B, validate system suitability, and provide a reliable procedure for routine quality control.

Methodology and Instrumentation

• Instrument: Shimadzu Nexera XR ultra-high performance liquid chromatograph
• Column: Shim-pack GIST C18 (150 mm × 4.6 mm i.d., 5 μm; USP code L1)
• Mobile phase: Gradient of aqueous solution A and methanol (40 % B initial to 70 % B at 10 min, held to 15 min, returned to 40 % B by 18 min)
• Flow rate: 1.0 mL/min; Column temperature: 45 °C; Injection volume: 5 μL
• Detection: Photodiode array at 350 nm and 260 nm

Main Results and Discussion

Chromatographic analysis yielded baseline separation of meloxicam and its impurities within a 17-minute run time.
The system suitability solution demonstrated consistent retention times and peak shapes, while the standard solution confirmed quantification accuracy.
The method reliably resolved meloxicam related compound B, meloxicam, and related compound A with adequate resolution conforming to USP criteria.

Benefits and Practical Applications

• Compliance with USP monograph ensures regulatory acceptance in pharmaceutical quality control.
• Efficient gradient program minimizes run time and solvent consumption.
• Robust detection at dual wavelengths enhances impurity identification.
• Applicability in QC laboratories for batch release and stability testing of meloxicam formulations.

Future Trends and Opportunities

Advances in UHPLC and core-shell column technologies may further reduce analysis time and solvent usage.
Integration with mass spectrometric detection could enhance impurity characterization.
Implementation of green chemistry principles may drive development of more sustainable mobile phases.

Conclusion

The presented RP‐HPLC method using Shim-pack GIST C18 columns and Nexera XR instrumentation meets USP requirements for meloxicam analysis.
It provides reliable separation, rapid analysis, and practical suitability for pharmaceutical quality control environments.

References

No specific literature references were provided in the source document.